Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


Master's course give graduates a degree of entrepreneurship

5 March 2013

"With coffee mornings, where students meet technology bosses, and a series of networking events, we are playing a lead role in the government's Silicon Roundabout technology enterprise zone," says Dr Dave Chapman (UCL Enterprise). Read: Guardian